Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Hawkeye Acquisition, Inc. (MDP) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/31/2021 GN Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees
03/08/2021 GN Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021
03/01/2021 GN Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021
02/25/2021 GN Medexus Announces Expanded Availability of Gleolan® in Canada
02/24/2021 GN Medexus Schedules Third Quarter Fiscal 2021 Conference Call
02/16/2021 GN Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side
02/03/2021 GN Medexus Announces Upsize to Previously Announced Bought Deal Public Offering
02/02/2021 GN Medexus Announces $20 Million Bought Deal Public Offering of Units
02/02/2021 GN Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
01/25/2021 GN Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®
01/21/2021 GN Medexus Submits Application to List on the Nasdaq
01/06/2021 GN Medexus Engages Independent Trading Group for Market Making Services
12/21/2020 GN Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors
12/08/2020 GN Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th
11/16/2020 GN Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 2020
11/16/2020 GN Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients
11/09/2020 GN Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call
10/30/2020 GN Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders
09/25/2020 GN Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy
09/18/2020 GN Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results
08/24/2020 GN Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants
08/24/2020 GN Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec's RAMQ List of Medications (Basic Plan and Institutions)
08/21/2020 GN Medexus Announces New U.S. Ticker “MEDXF” on the OTCQX
08/11/2020 GN Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of Fiscal 2021
06/22/2020 GN Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020
06/17/2020 GN Medexus Pharmaceuticals Schedules Fiscal Year 2020 Conference Call
06/03/2020 GN Medexus to Present at the Virtual Summer Summit on June 10th
05/22/2020 GN Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment
05/07/2020 GN Medexus Announces US$20 Million Asset-Based Credit Facility and Repays US$10 Million of its Term Loan
04/14/2020 GN MNI Targeted Media Launches CannabX, a Programmatic Ad Exchange for the Cannabis Industry
04/08/2020 GN Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada
03/23/2020 GN Medexus to Present at the Spring Investor Summit on March 25th
03/23/2020 GN Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic
03/10/2020 GN MNI Targeted Media Launches MNI OTT Optimization (motto™)
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy